Phase 1
N=10
A Phase I Study of LY3502970 in Healthy Participants
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT06085482 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Pharmacokinetics (PK): Absolute Bioavailability of LY3502970 — 77 Percentage
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- LY3502970 (Drug); [14C]-LY3502970 (Drug)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Eli Lilly and Company
- Primary completion
- Jan 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pharmacokinetics (PK): Absolute Bioavailability of LY3502970 |
77 | — |
| SECONDARY PK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma |
3.71 | — |
| SECONDARY PK: AUC [0-∞] of [14C]-LY3502970 in Plasma |
2.91 | — |
| SECONDARY PK: AUC [0-∞] of LY3502970 in Plasma |
108 | — |
| SECONDARY PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma |
2.10 | — |
| SECONDARY PK: Cmax of [14C]-LY3502970 in Plasma |
2.08 | — |
| SECONDARY PK: Cmax of LY3502970 in Plasma |
5.43 | — |
Summary
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.
Eligibility Criteria
Inclusion Criteria
- Are overtly healthy as determined by medical evaluation
- Participants with body weight of 45 kilograms (kg) or more and body mass index within the range 18.5 to 35.0 kilograms per meter squared (kg/m²), inclusive
- Males who agree to use highly effective or effective methods of contraception and women not of childbearing potential may participate in this study
Exclusion Criteria
- Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
- Women who are lactating and women of child bearing potential (WOCBP) are excluded from the study
- Participants who regularly use known drugs of abuse or show positive findings on drug screen
Data sourced from ClinicalTrials.gov (NCT06085482). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.